Business Description

Merck & Co Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
MRK.ArgentinaMRK.AustriaMRCK34.BrazilMRK.ChileMRK.France6MK.GermanyMRK.MexicoMRK.PeruMRK.RomaniaMRK.Switzerland0QAH.UKMRK.UkraineMRK.USA Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.37 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.68 | |||||
Debt-to-EBITDA | 1.51 | |||||
Interest Coverage | 25.15 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.5 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.7 | |||||
3-Year EBITDA Growth Rate | 10.5 | |||||
3-Year EPS without NRI Growth Rate | 28 | |||||
3-Year FCF Growth Rate | 7.1 | |||||
3-Year Book Growth Rate | 13.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10.85 | |||||
Future 3-5Y Total Revenue Growth Rate | 3.12 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 17.29 | |||||
9-Day RSI | 24.16 | |||||
14-Day RSI | 30.84 | |||||
6-1 Month Momentum % | 25.58 | |||||
12-1 Month Momentum % | 36.77 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.46 | |||||
Quick Ratio | 1.22 | |||||
Cash Ratio | 0.49 | |||||
Days Inventory | 129.35 | |||||
Days Sales Outstanding | 57.57 | |||||
Days Payable | 77.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.7 | |||||
Dividend Payout Ratio | 0.49 | |||||
3-Year Dividend Growth Rate | 9.9 | |||||
Forward Dividend Yield % | 2.82 | |||||
5-Year Yield-on-Cost % | 3.99 | |||||
3-Year Average Share Buyback Ratio | 0.8 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.63 | |||||
Operating Margin % | 30.84 | |||||
Net Margin % | 24.49 | |||||
ROE % | 35.84 | |||||
ROA % | 13.96 | |||||
ROIC % | 21.6 | |||||
ROC (Joel Greenblatt) % | 82.56 | |||||
ROCE % | 21.22 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 18.03 | |||||
Forward PE Ratio | 13.81 | |||||
PE Ratio without NRI | 18.03 | |||||
Shiller PE Ratio | 30.53 | |||||
Price-to-Owner-Earnings | 20.91 | |||||
PEG Ratio | 2.24 | |||||
PS Ratio | 4.41 | |||||
PB Ratio | 5.87 | |||||
Price-to-Tangible-Book | 135.09 | |||||
Price-to-Free-Cash-Flow | 17.14 | |||||
Price-to-Operating-Cash-Flow | 13.27 | |||||
EV-to-EBIT | 16.34 | |||||
EV-to-Forward-EBIT | 12.7 | |||||
EV-to-EBITDA | 13.9 | |||||
EV-to-Forward-EBITDA | 11.07 | |||||
EV-to-Revenue | 4.73 | |||||
EV-to-Forward-Revenue | 4.85 | |||||
EV-to-FCF | 18.37 | |||||
Price-to-Projected-FCF | 2.04 | |||||
Price-to-Median-PS-Value | 1.08 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.55 | |||||
Price-to-Graham-Number | 10.11 | |||||
Earnings Yield (Greenblatt) % | 6.12 | |||||
Forward Rate of Return (Yacktman) % | 14.34 |